Wire · regulatory
US weighs allowing most pharma licensing deals with China, sources say
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The US is drafting rules likely to allow most pharmaceutical licensing deals with Chinese companies, focusing restrictions on sensitive areas like pathogens and potential bioweapons, representing a looser approach than prior administrations and some congressional proposals.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must adjust your market access plans as the US is set to preserve licensing deals with China in drug development except in sensitive areas, opening capital flows and collaboration opportunities that Trump-era restrictions hindered. Moves you make now in negotiating China partnerships could unlock valuable new drugs for your pipeline as regulators ease controls.
◆ Coverage
1 source · 18 Sep 2026
◆ Related on Wire
◆ Topics